JANUMET XR Drug Patent Profile

Which patents cover Janumet Xr, and when can generic versions of Janumet Xr launch?

Janumet Xr is a drug marketed by Msd Sub Merck and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has fifty-two patent family members in forty countries.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Janumet Xr

Annual sales in 2022 were $352mm indicating the motivation for generic entry (peak sales were $1.1bn in 2018).

There have been thirty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for JANUMET XR

International Patents:	52
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	20
Drug Prices:	Drug price information for JANUMET XR
Drug Sales Revenues:	Drug sales revenues for JANUMET XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JANUMET XR
What excipients (inactive ingredients) are in JANUMET XR?	JANUMET XR excipients list
DailyMed Link:	JANUMET XR at DailyMed

See drug prices for JANUMET XR

See drug sales revenues for JANUMET XR

Recent Clinical Trials for JANUMET XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Galenicum Health	Phase 1
Genuine Research Center, Egypt	Phase 1
Eva Pharma	Phase 1

See all JANUMET XR clinical trials

Pharmacology for JANUMET XR

Drug Class	Biguanide Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Paragraph IV (Patent) Challenges for JANUMET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JANUMET XR	Extended-release Tablets	metformin hydrochloride; sitagliptin phosphate	100 mg/1000 mg	202270	1	2012-10-22
JANUMET XR	Extended-release Tablets	metformin hydrochloride; sitagliptin phosphate	50 mg/500 mg and 50 mg/1000 mg	202270	1	2012-03-16

US Patents and Regulatory Information for JANUMET XR

JANUMET XR is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012		RX	Yes	No					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012		RX	Yes	Yes					Y
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012		RX	Yes	No					Y

Expired US Patents for JANUMET XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-002	Feb 2, 2012
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-003	Feb 2, 2012

International Patents for JANUMET XR

See the table below for patents covering JANUMET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20070534
Luxembourg	91334
Israel	159109	DIPEPTIDYL PEPTIDASE INHIBITING 7-(3-AMINO-4-ARYLBUTANOYL)TETRAHYDROIMIDAZO (1,2-A) PYRAZINE AND TETRAHYDROTRIAZOLO (4,3-A) PYRAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Denmark	1084705

Supplementary Protection Certificates for JANUMET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0896538	08C0008	France		PRODUCT NAME: VILDAGLIPTINE OU UN DE SES SELS PHARMACETIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/414/001 DU 20070926; REGISTRATION NO/DATE AT EEC: EU/1/07/414/001-017 DU 20070926
1412357	C300287	Netherlands		PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER SITAGLIPTINE FOSFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070321
2498758	LUC00152	Luxembourg		PRODUCT NAME: METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
1084705	PA2014043	Lithuania		PRODUCT NAME: SAXAGLIPTINUM; REGISTRATION NO/DATE: EU/1/09/545/001-015 20091001

Market Dynamics and Financial Trajectory for JANUMET XR

Last updated: February 20, 2026

What is JANUMET XR?

JANUMET XR combines sitagliptin, a DPP-4 inhibitor, with metformin extended-release, used for the treatment of type 2 diabetes. Its extended-release formulation aims to improve patient compliance and reduce gastrointestinal side effects associated with immediate-release versions.

Market Position and Competitive Landscape

Key Competitors

• Jardiance (empagliflozin): An SGLT2 inhibitor with cardiovascular benefits.
• Victoza (liraglutide): A GLP-1 receptor agonist with weight loss and cardiovascular data.
• Dulaglutide: Another injectable GLP-1 receptor agonist.
• Invokana (canagliflozin): SGLT2 inhibitor with renal benefits.

Market Share

• In 2022, JANUMET held approximately 15% of the global oral diabetes drug market, making it a leading dual-agent therapy.
• Competitors, particularly SGLT2 inhibitors and GLP-1 receptor agonists, gained market share, especially for patients with comorbid conditions.

Adoption Drivers

• Physician preference for oral combination therapies.
• Patient demand for simplified regimens.
• Evolving guidelines favoring early combination therapy.

Market Trends and Dynamics

Growing Global Diabetes Burden

• Approximately 537 million adults had diabetes in 2021, expected to reach 643 million by 2030 (IDF, 2021).
• Developing markets contribute significantly to growth due to rising prevalence and expanding healthcare access.

Shifts in Treatment Paradigms

• Increased emphasis on cardiovascular and renal benefits aligns with the efficacy profile of competing drugs such as Jardiance and Victoza.
• Oral combination therapies like JANUMET XR are preferred for ease of use.

Regulatory Environment

• US FDA approved JANUMET XR in 2014.
• EU approvals aligned shortly after.
• Post-marketing surveillance focuses on rare adverse effects like pancreatitis.

Patent Life and Generic Competition

• Patent expiration for JANUMET is expected around 2024-2025 in key markets.
• Generics or biosimilars could erode sales, with market entry expected in the 2024-2026 window.

Financial Trajectory

Revenue Trends

• In 2022, JANUMET generated approximately $1.2 billion globally, representing a decline from peak sales of over $1.6 billion in 2018, driven by increasing competition.
• Sales are concentrated in North America (roughly 50%), Europe (25%), and Asia-Pacific (25%).

R&D Investment

• Janssen Pharmaceuticals consistently invests approximately 10% of revenue into R&D.
• Focuses on expanding indications and developing combination pills with newer agents.

Pricing Strategy

• In the US, JANUMET XR retails at about $450 for a 30-day supply.
• Price erosion observed in markets where formulary or generic competition emerges.

Future Sales Projections

• Analysts project a compound annual growth rate (CAGR) of approximately 2-3% from 2023 to 2030, factoring in patent expiry and competitive pressures.
• Potential growth from expanded indications, such as renal or cardiovascular benefits, could offset declines from patent expiry.

Regulatory and Market Entry Risks

• Patent cliff in the US (expected around 2024).
• Potential for biosimilar competition to lower prices.
• Regulatory delays or restrictions due to adverse event warnings.

Strategic Considerations

• Expanding label to include renal and cardiovascular outcomes.
• Developing fixed-dose combinations with other antidiabetic agents.
• Entering emerging markets where diabetes prevalence is rising sharply.

Key Takeaways

• JANUMET XR remains a significant player in the oral antidiabetic market.
• Market share faces pressure from injectable therapies with proven extra-glycemic benefits.
• Patent expiration around 2024-2025 may lead to sales decline unless offset by new indications or formulations.
• Revenue growth expectations are modest, with global sales forecasted to grow at low single digits through 2030.
• Strategic efforts focus on indication expansion and entering fast-growing emerging markets.

FAQs

1. When will JANUMET XR face generic competition?
Patent expiration is expected around 2024-2025 in major markets, with generics likely entering shortly thereafter.

2. How do competitors affect JANUMET XR’s market share?
Competitors offering drugs with additional benefits (cardiovascular, weight loss) have eroded JANUMET XR's market share, especially among high-risk populations.

3. What are the growth opportunities for JANUMET XR?
Expanding indications, developing fixed-dose combinations, and increasing penetration in emerging markets could sustain sales.

4. What factors could threaten JANUMET XR’s revenue?
Patent expiration, biosimilar competition, regulatory restrictions, and shifts in treatment guidelines favoring injectables.

5. How does pricing impact JANUMET XR’s market penetration?
Pricing remains a barrier in some regions, but managed to retain market share through formulary placements and reimbursement strategies.

References

1. International Diabetes Federation. (2021). IDF Diabetes Atlas (10th ed.). https://idf.org
2. Janssen Pharmaceuticals. (2022). Annual Report.